01Teva Pharmaceutical will report Q3 2026 earnings on November 3, 2026 after market close with analysts expecting $0.72 EPS versus $0.00 in the prior year.
02Revenue is projected at $4.2B, representing year-over-year growth from the previous year's quarter.
03The stock trades at $40.84 with a $34.6B market capitalization as of the article date.
04Teva missed Q2 2026 estimates significantly with $0.02 actual EPS against $0.41 expected, a 95.1% surprise miss.
05Investors should evaluate Q3 results within the context of recent quarterly trends showing volatility in earnings performance.
Analysts expect the Healthcare company to report earnings per share of $0.72, above the $0.00 reported in the same quarter last year. Revenue is expected to come in at $4.2B, up from a year ago.
Company Overview
The stock currently trades at $40.84 with a market capitalization of $34.6B.
Ahead of Teva Pharmaceutical Industries Limited's earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Teva Pharmaceutical Industries Limited should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Teva Pharmaceutical Industries Limited Earnings History